Find generic entry opportunities
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Crystalline Tiagabine monohydrate, its preparation and use|
|Abstract:||The invention provides crystalline Tiagabine hydrochloride monohydrate, process for its preparation, compositions containing the same and its therapeutic use as anti-epileptic agent.|
|Inventor(s):||Petersen; Henning (Lyngby, DK), Nielsen; Peter (Herlev, DK), Cain; Michael (Grayslake, IL), Patel; Subhash (Chicago, IL)|
|Assignee:||Novo Nordisk A/S (Bagsvaerd, DK)|
Patent Claim Types:|
see list of patent claims
|Compound; Process; Composition; Use;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Denmark||0582/91||Apr 02, 1991|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Germany||69229339||<disabled in preview>|
|Denmark||58291||<disabled in preview>|
|Denmark||0579681||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.